Scientists track immune cells in hepatitis d patients on new drug

NCT ID NCT06504485

Recruiting now Knowledge-focused Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how the immune system fights hepatitis D in people who also have hepatitis B. Researchers will measure special immune cells (T cells) in 192 adults before and after 12 months of treatment with the drug bulevirtide. The goal is to see if these immune responses relate to liver damage and whether the drug changes them.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bulevirtide
What this could lead to: If successful, this could help doctors understand why some patients respond to bulevirtide and others don't, potentially guiding better treatment choices for hepatitis D.
What could go wrong: This is an observational study, not a treatment trial. It is small (192 people) and single-center, so results may not apply to all patients. The findings may not lead to any new treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis D virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS D

Contacts and locations

Locations

Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy.
RECRUITING

Milan, 20122, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.